RECURSION PHARMACEUTICALS, INC. - 8-K Filing
Recursion Pharmaceuticals reports Q3 2026 results, extends cash runway into 2029, and appoints Fred Hassan as Board Chair. (Items: 2.02 Results of Operations and Financial Condition, 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Offi, 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $RXRX